Dr. Hossein Borghaei on Selecting Checkpoint Inhibitors in NSCLC

Hossein Borghaei, DO
Published: Monday, Oct 24, 2016


Hossein Borghaei, DO, associate professor at Fox Chase Cancer Center, discusses selecting between nivolumab (Opdivo) and pembrolizumab
(Keytruda) in second-line non–small cell lung cancer (NSCLC).
 
There is no head-to-head comparison of 1 agent versus the other, said Borghaei, so all oncologists have to go on are the clinical data from separate clinical trials. It is always difficult to do cross-trial comparisons, he said.
 
Scheduling is a factor in decision making, as nivolumab is given every 2 weeks versus pembrolizumab which is given every three weeks.
 
From a clinical decision-making process, most patients who are now in second-line, as long as they have reasonable performance status and can withstand any potential toxicity that could arise, would be candidates for treatment with either of these agents, said Borghaei.

Hossein Borghaei, DO, associate professor at Fox Chase Cancer Center, discusses selecting between nivolumab (Opdivo) and pembrolizumab
(Keytruda) in second-line non–small cell lung cancer (NSCLC).
 
There is no head-to-head comparison of 1 agent versus the other, said Borghaei, so all oncologists have to go on are the clinical data from separate clinical trials. It is always difficult to do cross-trial comparisons, he said.
 
Scheduling is a factor in decision making, as nivolumab is given every 2 weeks versus pembrolizumab which is given every three weeks.
 
From a clinical decision-making process, most patients who are now in second-line, as long as they have reasonable performance status and can withstand any potential toxicity that could arise, would be candidates for treatment with either of these agents, said Borghaei.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x